United Therapeutics: CEO's Multi-Million Dollar Sales Signal Caution Amidst Bullish Consensus

Related Articles

Fastly's Insider Exodus: Why CEO Sales Signal Caution Despite AI Hype

1 months ago

AXIA Energia's Insider Exodus: A Director's Sales Signal Caution Amidst Bullish Forecasts

1 months ago

Pitney Bowes' Rally: Why CEO Sales Signal Caution Despite a 10b5-1 Plan

1 months ago

BeOne Medicines: Why the CEO's $62 Million in Sales Casts a Shadow on Bullish Momentum

1 months ago

Category

You may also like

Stock News•1 week ago

Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million

Biotech executive Ian Clark sold 14,000 shares valued at $2.3 million, after exercising options at $50.57 while the precision oncology company trades near $160 per share.

GH

Share

Stock News•3 weeks ago

Is Tempus AI Stock a Buy After Its CEO Sold 250,000 Shares?

Tempus AI's founder-CEO cut an indirect stake ~4% via a pre-scheduled plan, retaining ~6.5M shares as the company pursues a major acquisition.

TEM

Share

Stock News•3 weeks ago

United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?

United Therapeutics CEO sold 9,500 shares (~$5.0M) at ~$530.42 on July 27, 2026, a 1% reduction in holdings. Insider retains ~669,000 shares.

UTHR

Share

Stock News•1 months ago

UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal

United Therapeutics acquired Thymmune, adding preclinical thymic cell therapy THY-100 to expand its regenerative medicine pipeline for organ transplantation.

UTHR

Share